AF
CCCC icon

Amalgamated Financial’s C4 Therapeutics CCCC Stock Holding History

Amalgamated Financial’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$153K Buy
+6,290
New +$153K ﹤0.01% 1996

Other funds holding CCCC

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Amalgamated Financial's CCCC Position: Q1 2022 in Review

Amalgamated Financial opened a new position in C4 Therapeutics (CCCC) in Q1 2022: 6,290 shares worth $153K. The stake represents ﹤0.01% of the portfolio and ranks #1996 among its holdings.

125 funds tracked by Wall St. Rank hold CCCC as of Q1 2022.

  • Amalgamated Financial held 6,290 shares of C4 Therapeutics worth $153K as of Q1 2022.
  • C4 Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • C4 Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1996 holding.
  • 125 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.